Immatics (IMTX) Operating Leases (2019 - 2026)
Immatics (IMTX) posted Operating Leases of $15.0 million for Q4 2025, down 5.02% sequentially from $15.8 million in Q3 2025, and up 5.06% YoY from $14.3 million in Q4 2024.
Analysis
Immatics (IMTX) Operating Leases (2019 - 2026) Analysis & Trends
Immatics has reported Operating Leases for 7 years, with the latest figure at $15.0 million in Q4 2025.
- Quarterly Operating Leases rose 5.06% year-over-year to $15.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.0 million (up 5.06% YoY) and the FY2025 annual result came in at $14.5 million, up 0.68% from the prior year.
- Operating Leases retreated to $15.0 million in Q4 2025 per IMTX's latest filing, from $15.8 million in the prior quarter.
- Over five years, Operating Leases peaked at $16.1 million in Q1 2025 and troughed at $5.2 million in Q3 2021.
- A 5-year average of $12.7 million and a median of $14.1 million in 2022 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2021 and 2022: Operating Leases decreased 9.22% in 2021, then soared 169.38% in 2022.
- Over 5 years, Operating Leases stood at $11.3 million in 2021, then advanced by 12.27% to $12.7 million in 2022, then increased by 8.82% to $13.8 million in 2023, then gained by 3.62% to $14.3 million in 2024, then increased by 5.06% to $15.0 million in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $15.0 million, $15.8 million, and $16.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.10 Mn |
| Mar 31, 2026 | 3.05 Mn |
| Dec 31, 2025 | 3.21 Mn |
| Sep 30, 2025 | 3.37 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Dec 31, 2024 | 3.05 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 3.42 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 2.80 Mn |
| Sep 30, 2023 | 3.04 Mn |
| Jun 30, 2023 | 2.98 Mn |
| Mar 31, 2023 | 2.63 Mn |
| Dec 31, 2022 | 2.20 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 3.11 Mn |
| Dec 31, 2021 | 3.10 Mn |
| Sep 30, 2021 | 3.07 Mn |